Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICARDIS HCT vs ALFUZOSIN HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.
Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.
Treatment of hypertension, alone or in combination with other antihypertensive agents
Treatment of benign prostatic hyperplasia (BPH),Off-label: Management of ureteral stones (medical expulsive therapy)
One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.
10 mg orally once daily immediately after the same meal each day. Extended-release tablet.
Telmisartan: terminal half-life ≈24 hours, allowing once-daily dosing. Hydrochlorothiazide: 6-15 hours (mean 10 hours).
Terminal elimination half-life: 5-7 hours in patients with benign prostatic hyperplasia; 7-10 hours in elderly; prolonged in hepatic impairment.
Telmisartan is primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT1A8; it is not metabolized by CYP450 enzymes. Hydrochlorothiazide is not extensively metabolized; it is eliminated unchanged in the urine.
Extensively metabolized in the liver, primarily via CYP3A4, to inactive metabolites.
Primarily biliary excretion (≈60%) and renal excretion (≈40%) as unchanged drug. Telmisartan: renal <1%, fecal >97%. Hydrochlorothiazide: renal >95% unchanged.
Primarily hepatic metabolism (CYP3A4); 11% renal excretion as unchanged drug; 69% fecal elimination (biliary), 24% urinary (total).
Telmisartan: >99.5% bound primarily to albumin and α1-acid glycoprotein. Hydrochlorothiazide: 40-68% bound to albumin.
82-90% bound to human serum albumin and alpha-1-acid glycoprotein.
Telmisartan: 500 L (≈7 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: 0.8-1.2 L/kg, confined to extracellular fluid.
Approximately 2.5-3.2 L/kg; indicates extensive extravascular distribution.
Telmisartan: absolute oral bioavailability ≈42-58% (dose-dependent). Hydrochlorothiazide: oral bioavailability ≈65-75%.
Oral immediate-release: 64% (first-pass metabolism); extended-release: 49% relative to immediate-release.
Contraindicated if GFR <30 m L/min. No adjustment needed for GFR 30-89 m L/min. Monitor renal function.
For Cr Cl 30-49 m L/min: 10 mg once daily; for Cr Cl <30 m L/min: contraindicated.
Contraindicated in severe hepatic impairment (Child-Pugh C). Caution and possible dose reduction in mild-to-moderate impairment; maximum 40 mg/12.5 mg daily.
Child-Pugh A: 10 mg once daily; Child-Pugh B or C: contraindicated.
Safety and efficacy not established in pediatric patients (<18 years).
Not established; safety and efficacy in children <18 years have not been studied.
No initial dose adjustment required; monitor blood pressure and renal function, especially with concurrent diuretic therapy.
No specific dose adjustment recommended; monitor for orthostatic hypotension and dizziness.
None
None.
Avoid use in pregnancy; can cause fetal harm when administered to a pregnant woman (discontinue as soon as possible when pregnancy is detected),May cause symptomatic hypotension in patients with volume or salt depletion,Monitor renal function; may cause acute renal failure, especially in patients with renal artery stenosis,Monitor serum electrolytes; risk of electrolyte imbalances (hypokalemia, hyponatremia, hypomagnesemia, hypercalcemia) due to hydrochlorothiazide,May exacerbate or activate systemic lupus erythematosus,May cause acute angle-closure glaucoma (due to hydrochlorothiazide),May cause hypersensitivity reactions, including anaphylaxis and angioedema (telmisartan),Use with caution in patients with hepatic impairment (telmisartan),Use with caution in patients with diabetes or impaired renal function; may increase risk of renal impairment when used with NSAIDs or COX-2 inhibitors,Monitor for hyperuricemia and gout,May cause photosensitivity reactions
Risk of hypotension, especially orthostatic hypotension, particularly with dose initiation or increase,May cause syncope, especially in patients with predisposing factors (e.g., hypovolemia, concurrent antihypertensives),Use with caution in patients with hepatic impairment,Intraoperative floppy iris syndrome (IFIS) during cataract surgery in patients on or previously treated with alpha-1 blockers,Should not be used in combination with other alpha-1 blockers
Hypersensitivity to telmisartan, hydrochlorothiazide, or any component of the formulation,Anuria (due to hydrochlorothiazide),Concomitant use with aliskiren in patients with diabetes mellitus,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment
Hypersensitivity to alfuzosin hydrochloride or any component of the formulation,Concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir),Moderate to severe hepatic impairment (Child-Pugh B or C)
Avoid high-potassium foods (bananas, oranges, tomatoes, spinach, salt substitutes) due to telmisartan's potassium-sparing effect. Hydrochlorothiazide may cause hypomagnesemia and hypokalemia; ensure adequate intake of magnesium-rich foods (nuts, whole grains) and potassium-rich foods (if not contraindicated). Avoid excessive alcohol intake which can increase hypotensive effect.
Take with food to reduce the risk of hypotension. Avoid grapefruit juice as it may increase alfuzosin levels. High-fat meals may alter absorption; consistency in meal timing is advised.
First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligohydramnios, skull ossification defects, hypotension, and anuria. Hydrochlorothiazide (HCTZ) may cause fetal or neonatal jaundice, thrombocytopenia, and electrolyte disturbances.
Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregnant women. First trimester: no evidence of fetal harm from animal data. Second and third trimesters: potential risk of maternal hypotension affecting uteroplacental perfusion; limited human data available.
Telmisartan is excreted in human milk in very low concentrations; M/P ratio unknown for telmisartan. Hydrochlorothiazide is excreted in breast milk; M/P ratio approximately 1.6. Avoid breastfeeding due to potential for adverse effects on the infant, including electrolyte disturbances and hypotension.
It is unknown if alfuzosin is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised due to potential for adverse effects in nursing infants, including hypotension. Alternative agents with more safety data are preferred during breastfeeding.
No dose adjustment data specific to pregnancy for Micardis HCT. Due to risk of fetal harm, use is contraindicated in pregnancy; discontinue as soon as pregnancy is detected. Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may theoretically require dose adjustment, but no established guidelines.
No specific dose adjustments are recommended due to lack of pharmacokinetic data in pregnancy. However, increased plasma volume during pregnancy may reduce drug levels; clinical effect should be monitored. Use lowest effective dose if necessary, and avoid in patients with severe hypotension or hypovolemia.
MICARDIS HCT (telmisartan/hydrochlorothiazide) is a fixed-dose combination for hypertension not controlled on monotherapy. Monitor renal function, electrolytes (especially potassium and sodium), and volume status. Avoid in severe renal impairment (Cr Cl <30 m L/min) and anuria. Assess for hypotension, particularly in volume-depleted patients. Use with caution in hepatic impairment, diabetes, and history of angioedema. May cause fetal harm in pregnancy; discontinue as soon as possible. Telmisartan is not dialyzable.
Alfuzosin is a selective alpha-1 adrenergic antagonist used for benign prostatic hyperplasia (BPH). It has fewer cardiovascular side effects than other alpha-blockers due to its higher affinity for alpha-1a receptors in the prostate. Do not use in patients with moderate to severe hepatic impairment. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Use with caution in patients with prolonged QT interval or on QT-prolonging drugs. Administer after the same meal each day to reduce first-dose syncope.
Take exactly as prescribed; do not skip doses or take double doses.,Notify your doctor immediately if you become pregnant or plan to become pregnant.,Avoid alcohol, NSAIDs, and salt substitutes containing potassium.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Report symptoms of electrolyte imbalance: muscle cramps, weakness, irregular heartbeat, confusion, or decreased urination.,This medication may increase blood sugar; monitor if you have diabetes.
Take this medication immediately after a meal at the same time each day.,Avoid situations that may cause dizziness or fainting, especially after the first dose or when increasing dose.,Do not crush, chew, or open the tablet; swallow whole.,Do not drive or operate heavy machinery until you know how the medication affects you.,Inform your doctor if you experience severe dizziness, fainting, or irregular heartbeat.,Avoid alcohol, which can increase dizziness and blood pressure-lowering effects.,Do not take with other alpha-blockers or medications for erectile dysfunction without consulting your doctor.
No interactions on record
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, can enhance the antihypertensive effect of Benidipine, a dihydropyridine calcium channel blocker. This occurs through additive vasodilation, potentially leading to excessive reductions in blood pressure. Clinically, patients may experience orthostatic hypotension, dizziness, or syncope, particularly during initial co-administration or dose adjustments."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, may potentiate the hypotensive effects of lamotrigine, an anticonvulsant. This interaction is primarily due to additive vasodilation, leading to an increased risk of orthostatic hypotension, dizziness, and syncope, particularly at the initiation of therapy or with dose adjustments. Patients, especially those with cardiovascular comorbidities, should be monitored for blood pressure changes and symptoms of hypotension."
"Alfuzosin, an alpha-1 adrenergic receptor antagonist used for benign prostatic hyperplasia, reduces peripheral vascular resistance by blocking alpha-1 receptors on vascular smooth muscle. Pentolinium, a ganglionic blocker, inhibits sympathetic outflow by competitively blocking nicotinic acetylcholine receptors at autonomic ganglia, leading to pronounced hypotension. When combined, their additive vasodilatory effects can cause excessive hypotension, increased risk of syncope, dizziness, and potential cardiovascular collapse, especially during initial therapy or dose escalation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICARDIS HCT vs ALFUZOSIN HYDROCHLORIDE, answered by our medical review team.
MICARDIS HCT is a Antihypertensive Combination (ARB + Thiazide Diuretic) that works by Micardis HCT is a combination of telmisartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Telmisartan selectively blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle and adrenal gland, leading to vasodilation and reduced aldosterone secretion. Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water, thereby reducing plasma volume.. ALFUZOSIN HYDROCHLORIDE is a Alpha-1 Blocker that works by Selective antagonist of postsynaptic alpha-1 adrenergic receptors in the prostate, bladder base, and prostatic urethra, leading to smooth muscle relaxation and improved urine flow.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICARDIS HCT and ALFUZOSIN HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICARDIS HCT is: One tablet orally once daily. Starting dose is 40 mg telmisartan / 12.5 mg hydrochlorothiazide; maximum 80 mg telmisartan / 25 mg hydrochlorothiazide.. The standard adult dose of ALFUZOSIN HYDROCHLORIDE is: 10 mg orally once daily immediately after the same meal each day. Extended-release tablet.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICARDIS HCT and ALFUZOSIN HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICARDIS HCT is classified as Category C. First trimester: Increased risk of fetal malformations based on angiotensin II receptor antagonist (ARB) class effects. Second and third trimesters: Fetal renal dysfunction, oligoh. ALFUZOSIN HYDROCHLORIDE is classified as Category C. Alfuzosin hydrochloride is classified as FDA Pregnancy Category B. Animal studies have not shown teratogenic effects, but there are no adequate and well-controlled studies in pregn. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.